Table 1.
Clinical characteristics of 251 P‐SCLC and 46 C‐SCLC patients
| Total | P‐SCLC | C‐SCLC | |||
|---|---|---|---|---|---|
| Characteristics | (n = 297) | (n = 251) | (n = 46) | P‐value | SMD |
| Age (years) | 57.04 ± 9.97 | 56.56 ± 10.12 | 59.65 ± 8.72 | 0.053 | 0.327 |
| Age group | |||||
| ≤60 years | 188 (63.3) | 164 (65.3) | 24 (52.2) | 0.124 | 0.270 |
| >60 years | 109 (36.7) | 87 (34.7) | 22 (47.8) | ||
| Gender | |||||
| Female | 87 (29.3) | 76 (30.3) | 11 (23.9) | 0.486 | 0.144 |
| Male | 210 (70.7) | 175 (69.7) | 35 (76.1) | ||
| Smoking | 195 (65.7) | 159 (63.3) | 36 (78.3) | 0.074 | 0.333 |
| Tumor laterality | |||||
| Left | 146 (49.2) | 126 (50.2) | 20 (43.5) | 0.498 | 0.135 |
| Right | 151 (50.8) | 125 (49.8) | 26 (56.5) | ||
| TNM stage (Seventh) | |||||
| I | 87 (29.3) | 78 (31.1) | 9 (19.6) | 0.469 | 0.269 |
| II | 85 (28.6) | 70 (27.9) | 15 (32.6) | ||
| III | 115 (38.7) | 95 (37.8) | 20 (43.5) | ||
| IV | 10 (3.4) | 8 (3.2) | 2 (4.3) | ||
| VALSG stage | |||||
| Extensive | 11 (3.7) | 9 (3.6) | 2 (4.3) | 0.682 | 0.039 |
| Limited | 286 (96.3) | 242 (96.4) | 44 (95.7) | ||
| Lymph node metastasis | 183 (61.6) | 153 (61.0) | 30 (65.2) | 0.703 | 0.088 |
| Treatment | |||||
| S | 35 (11.8) | 32 (12.7) | 3 (6.5) | 0.485 | 0.223 |
| S + CTx | 166 (55.9) | 140 (55.8) | 26 (56.5) | ||
| S + CTx + RT | 96 (32.3) | 79 (31.5) | 17 (37.0) | ||
| Extent of resection † | |||||
| Lobectomy | 236 (79.5) | 200 (79.7) | 36 (78.3) | 0.623 | 0.162 |
| Pneumonectomy | 20 (6.7) | 18 (7.2) | 2 (4.3) | ||
| Sublobectomy | 19 (6.4) | 15 (6.0) | 4 (8.7) | ||
| CTx before S | 27 (9.1) | 25 (10.0) | 2 (4.3) | 0.278 | 0.219 |
| Chemotherapy | 262 (88.2) | 219 (87.3) | 43 (93.5) | 0.339 | 0.212 |
| Radiation | 96 (32.3) | 79 (31.5) | 17 (37.0) | 0.576 | 0.116 |
| PCI | 66 (22.2) | 59 (23.5) | 7 (15.2) | 0.294 | 0.211 |
| Chemo‐regmen ‡ | |||||
| SCLC regimen | 167 (56.2) | 150 (59.8) | 17 (37.0) | <0.001 * | 1.069 |
| NSCLC regimen | 9 (3.0) | 0 (0.0) | 9 (19.6) | ||
| SCLC + NSCLC regimen | 7 (2.4) | 3 (1.2) | 4 (8.7) | ||
| No chemotherapy | 35 (11.8) | 32 (12.7) | 3 (6.5) | ||
| Follow‐up § | |||||
| DM | 72 (24.2) | 64 (25.5) | 8 (17.4) | 0.687 | 0.228 |
| IR | 38 (12.8) | 31 (12.4) | 7 (15.2) | ||
| IR + DM | 22 (7.4) | 20 (8.0) | 2 (4.3) | ||
| No recurrence | 152 (51.2) | 129 (51.4) | 23 (50.0) | ||
AJCC, American Joint Committee on Cancer; C‐SCLC, combined small cell lung cancer; CTx, chemotherapy; DM, distant metastasis; IR, intrathoracic recurrence; PCI, prophylactic cranial irradiation; P‐SCLC, pure small cell lung cancer; RT, radiotherapy; S, surgery; SMD, standard mean difference; VALSG, Veterans Administration Lung Study Group.
†
22 patients were excluded because the surgical information was unavailable.
‡
79 patients were excluded because the chemotherapy regimen was unknown.
§
13 patients were excluded because the sites of recurrence was not recorded.
*
P < 0.05 is indicated by bold italics.